{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T05:46:13Z","timestamp":1771307173497,"version":"3.50.1"},"reference-count":69,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Laboratory Medicine"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.cll.2023.04.010","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T18:46:33Z","timestamp":1685645193000},"page":"351-361","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Advances in Monitoring and Prognostication for Lymphoma by Flow Cytometry"],"prefix":"10.1016","volume":"43","author":[{"given":"Amrit P.","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth L.","family":"Courville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cll.2023.04.010_bib1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/ajcp\/aqaa242","article-title":"How I diagnose minimal\/measurable residual disease in B lymphoblastic leukemia\/lymphoma by flow cytometry","volume":"155","author":"Cherian","year":"2021","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"10.1016\/j.cll.2023.04.010_bib2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/cyto.b.21249","article-title":"Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition","volume":"90","author":"Stetler-Stevenson","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"issue":"1","key":"10.1016\/j.cll.2023.04.010_bib3","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/cyto.b.21595","article-title":"Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: an European Research initiative on CLL (ERIC) & European Society for clinical cell analysis (ESCCA) Harmonisation project","volume":"94","author":"Rawstron","year":"2018","journal-title":"Cytometry B Clin Cytom"},{"issue":"6","key":"10.1016\/j.cll.2023.04.010_bib4","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1309\/AJCPBV9ELXC0ECVL","article-title":"Differential expression of CD200 in B-cell neoplasms by flow cytometry can assist in diagnosis, subclassification, and bone marrow staging","volume":"142","author":"Challagundla","year":"2014","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.cll.2023.04.010_bib5","doi-asserted-by":"crossref","first-page":"584427","DOI":"10.3389\/fonc.2020.584427","article-title":"CD200 and chronic lymphocytic leukemia: biological and clinical relevance","volume":"10","author":"D'Arena","year":"2020","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.cll.2023.04.010_bib6","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.leukres.2009.01.017","article-title":"CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia","volume":"33","author":"Palumbo","year":"2009","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.cll.2023.04.010_bib7","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrclinonc.2010.167","article-title":"Prognostic factors in chronic lymphocytic leukemia-what do we need to know?","volume":"8","author":"Cramer","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.cll.2023.04.010_bib8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.blre.2008.05.003","article-title":"Prognostic markers in chronic lymphocytic leukemia: a comprehensive review","volume":"23","author":"Van Bockstaele","year":"2009","journal-title":"Blood Rev"},{"issue":"2","key":"10.1016\/j.cll.2023.04.010_bib9","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s11899-018-0439-9","article-title":"Prognostic factors in the era of targeted therapies in CLL","volume":"13","author":"Boddu","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.cll.2023.04.010_bib10","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.cca.2018.04.026","article-title":"ZAP-70 in chronic lymphocytic leukemia: a meta-analysis","volume":"483","author":"Liu","year":"2018","journal-title":"Clin Chim Acta"},{"issue":"4","key":"10.1016\/j.cll.2023.04.010_bib11","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/cyto.b.20121","article-title":"ZAP-70 by flow cytometry: a comparison of different antibodies, anticoagulants, and methods of analysis","volume":"70","author":"Best","year":"2006","journal-title":"Cytometry B Clin Cytom"},{"issue":"1","key":"10.1016\/j.cll.2023.04.010_bib12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/cyto.b.21384","article-title":"CD49d shows superior performance characteristics for flow cytometric prognostic testing in chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"94","author":"Gooden","year":"2018","journal-title":"Cytometry B Clin Cytom"},{"issue":"9","key":"10.1016\/j.cll.2023.04.010_bib13","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1200\/JCO.2013.50.8515","article-title":"CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia","volume":"32","author":"Bulian","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.cll.2023.04.010_bib14","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1365-2141.2007.06965.x","article-title":"CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential","volume":"140","author":"Shanafelt","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cll.2023.04.010_bib15","doi-asserted-by":"crossref","first-page":"106169","DOI":"10.1016\/j.leukres.2019.106169","article-title":"CD200 and prognosis in chronic lymphocytic leukemia: conflicting results","volume":"83","author":"D'Arena","year":"2019","journal-title":"Leuk Res"},{"issue":"12","key":"10.1016\/j.cll.2023.04.010_bib16","doi-asserted-by":"crossref","first-page":"13551","DOI":"10.18632\/oncotarget.6948","article-title":"Low expression of CD200 predicts shorter time-to-treatment in chronic lymphocytic leukemia","volume":"7","author":"Miao","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.cll.2023.04.010_bib17","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00277-022-04756-4","article-title":"Identification of CD105 (endoglin) as novel risk marker in CLL","volume":"101","author":"Greiner","year":"2022","journal-title":"Ann Hematol"},{"issue":"11","key":"10.1016\/j.cll.2023.04.010_bib18","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/ajh.25595","article-title":"Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment","volume":"94","author":"Hallek","year":"2019","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.cll.2023.04.010_bib19","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/ejh.13833","article-title":"Implementation of International Prognostic Index with flow cytometry immunophenotyping for better risk stratification of chronic lymphocytic leukemia","volume":"109","author":"Giudice","year":"2022","journal-title":"Eur J Haematol"},{"issue":"10","key":"10.1016\/j.cll.2023.04.010_bib20","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1080\/10428194.2022.2090551","article-title":"CD38 as a multifaceted immunotherapeutic target in CLL","volume":"63","author":"Paulus","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"19","key":"10.1016\/j.cll.2023.04.010_bib21","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.3390\/cancers14194917","article-title":"CD20 expression as a possible novel prognostic marker in CLL: application of EuroFlow Standardization technique and normalization procedures in flow cytometric expression analysis","volume":"14","author":"Schilhabel","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.cll.2023.04.010_bib22","unstructured":"National Comprehensive Cancer Network. Chronic lymphocytic Leukemia\/Small Lymphocytic Lymphoma (Version 1.2022). Available at: https:\/\/www.nccn.org\/guidelines\/category_1. Accessed 12 September, 2021."},{"issue":"4","key":"10.1016\/j.cll.2023.04.010_bib23","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/leu.2015.313","article-title":"A\u00a0complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study","volume":"30","author":"Rawstron","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.cll.2023.04.010_bib24","doi-asserted-by":"crossref","first-page":"597730","DOI":"10.3389\/fonc.2020.597730","article-title":"Highly sensitive and accurate assessment of minimal residual disease in chronic lymphocytic leukemia using the novel cd160-ROR1 assay","volume":"10","author":"Farren","year":"2020","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.cll.2023.04.010_bib25","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/labmed\/lmw006","article-title":"Optimization and validation of an 8-color single-tube assay for the sensitive detection of minimal residual disease in B-cell chronic lymphocytic leukemia detected via flow cytometry","volume":"47","author":"Dowling","year":"2016","journal-title":"Lab Med"},{"key":"10.1016\/j.cll.2023.04.010_bib26","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.humpath.2021.11.001","article-title":"Mantle cell lymphoma with chronic lymphocytic leukemia-like features: a diagnostic mimic and pitfall","volume":"119","author":"Qiu","year":"2022","journal-title":"Hum Pathol"},{"issue":"2","key":"10.1016\/j.cll.2023.04.010_bib27","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1309\/AJCP8FOIVTB6LBER","article-title":"Lymphoplasmacytic lymphoma and other non-marginal zone lymphomas with plasmacytic differentiation","volume":"136","author":"Lin","year":"2011","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"10.1016\/j.cll.2023.04.010_bib28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/10428194.2021.1973670","article-title":"CD5 expression in marginal zone lymphoma predicts differential response to rituximab or bendamustine\/rituximab","volume":"63","author":"Hsu","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.cll.2023.04.010_bib29","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/cytob.21210","article-title":"Detection of minimal residual disease in mantle cell lymphoma-establishment of novel eight-color flow cytometry approach","volume":"88","author":"Chovancova","year":"2015","journal-title":"Cytometry B Clin Cytom"},{"issue":"3","key":"10.1016\/j.cll.2023.04.010_bib30","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3324\/haematol.2015.134957","article-title":"Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study","volume":"101","author":"Cheminant","year":"2016","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.cll.2023.04.010_bib31","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13045-020-00961-8","article-title":"Advances in the assessment of minimal residual disease in mantle cell lymphoma","volume":"13","author":"Jung","year":"2020","journal-title":"J\u00a0Hematol Oncol"},{"issue":"5","key":"10.1016\/j.cll.2023.04.010_bib32","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.hoc.2020.06.006","article-title":"Minimal residual disease in mantle cell lymphoma: methods and clinical significance","volume":"34","author":"Ladetto","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"issue":"3","key":"10.1016\/j.cll.2023.04.010_bib33","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/j.seminhematol.2011.05.002","article-title":"Minimal residual disease detection in mantle cell lymphoma: technical aspects and clinical relevance","volume":"48","author":"Pott","year":"2011","journal-title":"Semin Hematol"},{"issue":"26","key":"10.1016\/j.cll.2023.04.010_bib34","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMra2202672","article-title":"Mantle-cell lymphoma","volume":"386","author":"Armitage","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.cll.2023.04.010_bib35","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.cll.2023.04.010_bib36","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1309\/2GFKU23XA1DH38L7","article-title":"Abnormal patterns of antigenic expression in follicular lymphoma: a flow cytometric study","volume":"124","author":"Ray","year":"2005","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"10.1016\/j.cll.2023.04.010_bib37","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/pin.12145","article-title":"CD5-positive follicular lymphoma characterized by CD25, MUM1, low frequency of t(14;18) and poor prognosis","volume":"64","author":"Miyoshi","year":"2014","journal-title":"Pathol Int"},{"issue":"6","key":"10.1016\/j.cll.2023.04.010_bib38","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/modpathol.2015.42","article-title":"CD5-positive follicular lymphoma: clinicopathologic correlations and outcome in 88 cases","volume":"28","author":"Li","year":"2015","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.cll.2023.04.010_bib39","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1158\/1078-0432.CCR-09-2487","article-title":"A\u00a0unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1--positive, regulatory, cytotoxic, and helper T\u00a0cells and macrophages","volume":"16","author":"Wahlin","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"2 Pt 1","key":"10.1016\/j.cll.2023.04.010_bib40","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/1078-0432.CCR-06-1734","article-title":"CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma","volume":"13","author":"Wahlin","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.cll.2023.04.010_bib41","doi-asserted-by":"crossref","first-page":"e002662","DOI":"10.1136\/jitc-2021-002662","article-title":"Expression of KLRG1 and CD127 defines distinct CD8(+) subsets that differentially impact patient outcome in follicular lymphoma","volume":"9","author":"Wu","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"4","key":"10.1016\/j.cll.2023.04.010_bib42","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1080\/10428194.2016.1217525","article-title":"T-cell subsets in lymph nodes identify a subgroup of follicular lymphoma patients with favorable outcome","volume":"58","author":"Magnano","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.cll.2023.04.010_bib43","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/978-1-4939-9151-8_9","article-title":"MRD detection in B-cell non-Hodgkin lymphomas using ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR","volume":"1956","author":"Pott","year":"2019","journal-title":"Methods Mol Biol"},{"issue":"5","key":"10.1016\/j.cll.2023.04.010_bib44","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/cyto.b.21770","article-title":"Bright CD38 expression by flow cytometric analysis is a biomarker for double\/triple Hit lymphomas with a moderate sensitivity and high Specificity","volume":"96","author":"Alsuwaidan","year":"2019","journal-title":"Cytometry B Clin Cytom"},{"issue":"1","key":"10.1016\/j.cll.2023.04.010_bib45","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.pathol.2017.09.006","article-title":"Diffuse large B-cell lymphoma","volume":"50","author":"Li","year":"2018","journal-title":"Pathology"},{"issue":"5","key":"10.1016\/j.cll.2023.04.010_bib46","doi-asserted-by":"crossref","first-page":"602","DOI":"10.5858\/arpa.2014-0086-RA","article-title":"Clinical prognostic biomarkers in chronic lymphocytic leukemia and diffuse large B-cell lymphoma","volume":"139","author":"Chastain","year":"2015","journal-title":"Arch Pathol Lab Med"},{"issue":"4","key":"10.1016\/j.cll.2023.04.010_bib47","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1309\/AJCPPHMZ6VHF0WQV","article-title":"p53 expression is a strong marker of inferior survival in de novo diffuse large B-cell lymphoma and may have enhanced negative effect with MYC coexpression: a single institutional clinicopathologic study","volume":"141","author":"Xie","year":"2014","journal-title":"Am J Clin Pathol"},{"issue":"20","key":"10.1016\/j.cll.2023.04.010_bib48","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","article-title":"MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from the International DLBCL Rituximab-CHOP Consortium Program","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cll.2023.04.010_bib49","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cll.2023.04.010_bib50","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/ajh.24299","article-title":"De novo CD5+ diffuse large B-cell lymphoma: adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort","volume":"91","author":"Alinari","year":"2016","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.cll.2023.04.010_bib51","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/ejh.12847","article-title":"Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH","volume":"98","author":"Thakral","year":"2017","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.cll.2023.04.010_bib52","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1182\/blood.V99.3.815","article-title":"De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients","volume":"99","author":"Yamaguchi","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cll.2023.04.010_bib53","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/hon.2904","article-title":"CD38 expression is an important prognostic marker in diffuse large B-cell lymphoma","volume":"39","author":"Wada","year":"2021","journal-title":"Hematol Oncol"},{"issue":"3","key":"10.1016\/j.cll.2023.04.010_bib54","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3324\/haematol.2014.110189","article-title":"Revisiting the immune microenvironment of diffuse large B-cell lymphoma using a tissue microarray and immunohistochemistry: robust semi-automated analysis reveals CD3 and FoxP3 as potential predictors of response to R-CHOP","volume":"100","author":"Coutinho","year":"2015","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.cll.2023.04.010_bib55","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/ajcp\/aqw034","article-title":"Prognostic impact of tumor microenvironment in diffuse large B-cell lymphoma uniformly treated with R-CHOP chemotherapy","volume":"145","author":"Gomez-Gelvez","year":"2016","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.cll.2023.04.010_bib56","unstructured":"WHO Classification of Tumours Editorial Board. Haematolymphoid tumours Internet; beta version ahead of print. Lyon (France): International Agency for Research on Cancer; 2022 cited 2022 Dec 1. (WHO classification of tumours series, 5th ed.; vol. 11). Available at: https:\/\/tumourclassification.iarc.who.int\/chapters\/63. In."},{"issue":"3","key":"10.1016\/j.cll.2023.04.010_bib57","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1309\/3A32DTVMH640M2QA","article-title":"Flow cytometric assessment of TCR-Vbeta expression in the evaluation of peripheral blood involvement by T-cell lymphoproliferative disorders: a comparison with conventional T-cell immunophenotyping and molecular genetic techniques","volume":"121","author":"Morice","year":"2004","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"10.1016\/j.cll.2023.04.010_bib58","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1093\/ajcp\/aqy173","article-title":"Utility of a Simple and robust flow cytometry assay for rapid clonality testing in mature peripheral T-cell lymphomas","volume":"151","author":"Novikov","year":"2019","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"10.1016\/j.cll.2023.04.010_bib59","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1182\/blood.V98.1.165","article-title":"Molecular and flow cytometric analysis of the Vbeta repertoire for clonality assessment in mature TCRalphabeta T-cell proliferations","volume":"98","author":"Langerak","year":"2001","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cll.2023.04.010_bib60","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/ajcp\/aqaa214","article-title":"Single-antibody evaluation of T-cell receptor beta constant chain monotypia by flow cytometry facilitates the diagnosis of T-cell large granular lymphocytic leukemia","volume":"156","author":"Horna","year":"2021","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"10.1016\/j.cll.2023.04.010_bib61","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/bjd.21678","article-title":"TRBC1 expression assessed by flow cytometry as a novel marker of clonality in cutaneous alphabeta T-cell lymphomas with peripheral blood involvement","volume":"187","author":"Martin-Moro","year":"2022","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.cll.2023.04.010_bib62","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jid.2020.09.011","article-title":"Utility of TRBC1 expression in the diagnosis of peripheral blood involvement by cutaneous T-cell lymphoma","volume":"141","author":"Horna","year":"2021","journal-title":"J\u00a0Invest Dermatol"},{"issue":"3","key":"10.1016\/j.cll.2023.04.010_bib63","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/cyto.b.21881","article-title":"Flow cytometric evaluation of TRBC1 expression in tissue specimens and body fluids is a novel and specific method for assessment of T-cell clonality and diagnosis of T-cell neoplasms","volume":"100","author":"Berg","year":"2021","journal-title":"Cytometry B Clin Cytom"},{"issue":"4","key":"10.1016\/j.cll.2023.04.010_bib64","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/labmed\/lmac014","article-title":"Reliable detection of T-cell clonality by flow cytometry in mature T-cell neoplasms using TRBC1: implementation as a reflex test and comparison with PCR-based clonality testing","volume":"53","author":"Waldron","year":"2022","journal-title":"Lab Med"},{"issue":"17","key":"10.1016\/j.cll.2023.04.010_bib65","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.3390\/cancers13174379","article-title":"Anti-TRBC1 antibody-based flow cytometric detection of T-cell clonality: Standardization of sample preparation and diagnostic implementation","volume":"13","author":"Munoz-Garcia","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.cll.2023.04.010_bib66","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/cyto.b.21782","article-title":"Single antibody detection of T-cell receptor alphabeta clonality by flow cytometry rapidly identifies mature T-cell neoplasms and monotypic small CD8-positive subsets of uncertain significance","volume":"98","author":"Shi","year":"2020","journal-title":"Cytometry B Clin Cytom"},{"issue":"2","key":"10.1016\/j.cll.2023.04.010_bib67","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/cyto.b.21878","article-title":"Flow cytometric evaluation of peripheral blood for suspected Sezary syndrome or mycosis fungoides: International guidelines for assay characteristics","volume":"100","author":"Horna","year":"2021","journal-title":"Cytometry B Clin Cytom"},{"issue":"3","key":"10.1016\/j.cll.2023.04.010_bib68","doi-asserted-by":"crossref","first-page":"285","DOI":"10.6004\/jnccn.2022.0015","article-title":"T-cell lymphomas, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Horwitz","year":"2022","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.cll.2023.04.010_bib69","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/ajcp\/aqy129","article-title":"False-positive light chain clonal restriction by flow cytometry in patients treated with alemtuzumab: potential pitfalls for the misdiagnosis of B-cell neoplasms","volume":"151","author":"Chen","year":"2019","journal-title":"Am J Clin Pathol"}],"container-title":["Clinics in Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271223000483?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271223000483?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T10:09:31Z","timestamp":1715594971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272271223000483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0272271223000483"],"URL":"https:\/\/doi.org\/10.1016\/j.cll.2023.04.010","relation":{},"ISSN":["0272-2712"],"issn-type":[{"value":"0272-2712","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in Monitoring and Prognostication for Lymphoma by Flow Cytometry","name":"articletitle","label":"Article Title"},{"value":"Clinics in Laboratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cll.2023.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}